The PROVA Study Group. (1991) Prophylaxis offirst hemorrhage from esophageal oarices by sclerotherapy, propranolol or both in cirrhotic patients: A randomized multicenter trial. Hepatology; 14,[1016][1017][1018][1019][1020][1021][1022][1023][1024] The objective of this randomized multicenter trial was to assess the prophylactic effect on the incidence and severity of the first variceal hemorrhage of endoscopic sclerotherapy, propranolol and the combination of the two compared with none of these treatments in patients with cirrhosis and esophageal varices. Among 819 cirrhotic patients who never had experienced variceal bleeding, esophagoscopy revealed varices in 379, of whom 286 were enrolled in the trial; 73 were allocated to sclerotherapy (paravenous polidocanoi [10 mg/mi] every 1 to 2 wk until eradication), 68 to propranolol (slow-release preparation in one daily dose adjusted to provide about 25% heart rate reduction), 73 to both treatments and 72 to neither of the two treatments. The patients were observed for up to 42 months, with an ,average of 15 months. After variceal bleeding, patients in all groups received sclerotherapy only. The incidences of variceal bleeding (n 50) were almost identical in the four groups. The relative risk (with 95% confidence limits) with sclerotherapy was 1.06 (0.61 to 1.84), and the relative risk with propranolol was 0.92 (0.53 to 1.60). The mortality rate after variceal bleeding (n 29) did not differ significantly either. The mortality rate without variceal bleeding (n 46) was 2.75 (1.45 to 5.22) times higher in the sclerotherapy groups than in the nonsclerotherapy groups (p 0.002), whereas propranolol showed no effect, the relative risk being 1.17 (0.66 to 2.10). The total mortality rate showed no significant difference between the sclerotherapy, propranolol and control groups, but the combined therapy group had a significantly increased mortality rate.
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This is a Danish study from the PROVA study group, which compares endoscopic sclerotherapy, propranolol, the combination of the two and a control group for the prevention and effect on severity of the first variceal haemorrhage. Previous transfusion) in the injected group; 9 (7 needing transfusion) in the combined group; 11 (7 needing transfusion) in the propranolol group; and 6 (4 needing transfusion) in the control group.
The mortality rate after variceal bleeding was the same, but the mortality without variceal bleeding was 2.75 times higher, 95% confidence limits (1.45-5.22) in the sclerotherapy groups compared to the non-sclerotherapy groups (p 0.002), whereas propranolol had no effect. The total mortality rate was increased in the combined treatment group. This was confirmed when co-variables with an independent predictive value for mortality were assessed. This necessitated stopping the trial early. This effect of sclerotherapy was also seen in the Veterans Administration trial in the USA3, in which the increased mortality seen with sclerotherapy, was not due to an increase in bleeding-related deaths, and in which the excess mortality disappeared once sclerotherapy was stopped. This trial was also stopped early.
In this Danish study sclerotherapy achieved eradication of varices in 66% of the group who only had injection, and in 67% of the combined treatment group. These figures are comparable to other trials and do not suggest an "aggressive" sclerotherapy programme which could be directly implicated in causing the excess deaths.
Moreover, although complications of sclerotherapy were frequent these did not contribute to the mortality: oesophageal stricture (n= 10), ulceration (n=9), mediastinitis and septicaemia (n 1), aphonia (n 1), recurrent pulmonary emboli (n= 1) and a perforation without sequelae (n= 1). In the propranolol group: dizziness (n 9), cold extremities (n 8), hypotension (n 7), bradycardia (n 4), orthostatic hypotension (n 3), heart failure (n 3), fatigue (n 3), nightmares (n=2), asthma (n=3), acute cardiac failure (n=l). These complications are similar to other beta-blocker trials. Discontinuation of propranolol occurred in only 19% of the group treated with drug alone (n 7 side effects, n 5 withdrawal) and 13% (n 3 side effects, n 5 withdrawal) of the combined group again similar to previous trials. These two aspects of beta-blockade do not suggest that the drug treatment groups had a more favourable response than in other trials, thus potentially accentuating the differences between beta-blockers and sclerotherapy.
Moreover, these aspects do not explain the lack of therapeutic efficacy of propranolol seen in this trial.
The authors comment that their results with propranolol are compatible with the range of effect evidenced from an updated meta-analysis of beta-blocker trials4. Thus the different result may simply be due to random sampling variation. 
